Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857611 | 1.00 | SMN1; SMN2 (0.75) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL11118030 | 0.86 | SMN1; SMN2 (0.88) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL561667 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL5512536 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL5328441 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL5328444 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL188811 | 0.80 | SMN1; SMN2 (0.70) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL17124702 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL19222685 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL15015776 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143416-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143416-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143416-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20110137044-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20110137044-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20110137044-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-7910774-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| US-7910774-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| US-7910774-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| EP-1789377-B1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| EP-1978012-A1 | Alternative synthesis of renin inhibitors and intermediates thereof | Novartis AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-20070208055-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208055-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208055-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| WO-2006024501-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137044-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | REN, ACE, AGT | SMN1; SMN2 4826/4885CA14 1293/4885CA12 1437/4885 |
| US-20070208055-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | REN, ACE, AGT | SMN1; SMN2 4833/4885CA14 1308/4885CA12 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.